Effects of Donepezil on Deficits Associated With Age-Related Decrease of Growth Hormone

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The planned study has two purposes:

1. It is to provide evidence that the administration of a cholinesterase inhibitor will result in an increase of IGF-I (primary variable) and in an increase of the secretion growth hormone (secondary variable) that can be maintained throughout the treatment-period of one year.

2. The study also tests the hypothesis that maintenance of increased blood levels of growth hormone and IGF-I can stop or delay the age-related changes of body composition (secondary variables) .

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ludwig Boltzmann Gesellschaft
• Treatments: Cholinesterase Inhibitors; Donepezil; Hormones

Criteria

Inclusion Criteria:

• Aged between 70 and 80 years

Exclusion Criteria:

• Cardiac arrhythmias (sick sinus syndrome, AV block, sino-atrial block),

• Treatment with beta-blockers, NSAIDs or cholinergic agonists,

• Known hypersensitivity to donepezil hydrochloride, piperidine derivatives or to any excipients used in the formulation,

• Gastric and duodenal ulcer,

• Severe renal and hepatic impairment,

• Urinary congestion (prostatic hypertrophy),

• Obstructive pulmonary disease (bronchial asthma);